micvotabart pelidotin
micvotabart pelidotin: developed by 1 company · 2 clinical trials tracked.
micvotabart pelidotin evidence translation
What we can confirm
2 tracked trials
What it means
What to watch
Prepared research question
How could micvotabart pelidotin → PYXS affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence4 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (2)
| Company | Phase |
|---|---|
| Pyxis Oncology, Inc. (PYXS) Advanced Solid Tumors; Solid Tumor | Phase 1/Phase 2 |
| Pyxis Oncology, Inc. (PYXS) recurrent and metastatic head and neck squamous cell carcino… | Phase 1/Phase 2 |
Clinical Trials (2)
A Phase 1/2, Open-label, Global, Multicenter, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PYX-201 in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
Primary endpoint: Number of Participants who Experience a Dose-Limiting Toxicity (DLT)
A First-in-Human, Open-label, Multicenter, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PYX-201 in Participants With Advanced Solid Tumors
Primary endpoint: Number of Participants who Experience a Dose-limiting Toxicity (DLT) in Dose Escalation
Frequently asked questions
Who is developing micvotabart pelidotin?
micvotabart pelidotin is being developed by Pyxis Oncology, Inc..
How many clinical trials involve micvotabart pelidotin?
BioSniper tracks 2 clinical trials involving micvotabart pelidotin.